Patent ID: 9630954
Date: 2017-04-25
CPC Classifications: A61K,C07C,C07D

Claim:
1. A method for treating rheumatoid arthritis, comprising administering an inhibitor of interaction between T cells and a complex of MHC-II and human collagen type II or an antigenic fragment thereof to a patient who is HLA-DR4 positive, HLA-DR7 positive, or both HLA-DR4 positive and HLA-DR7 positive; wherein said inhibitor is a compound of formula (I): wherein R is selected from the group consisting of hydrogen, a methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, phenylethyl group, and substituted o-chloro, o-bromo or o-iodo forms thereof; R1 is selected from the group consisting of: phenyl, 2′-pyridyl, 3′-pyridyl, 4′-pyridyl, o-iodophenyl, m-iodophenyl, p-iodophenyl, o-chlorophenyl, m-chlorophenyl, and p-chlorophenyl; and is in the form of a diastereoisomeric mixture, racemic mixture, isolated enantiomer, or salts thereof.